CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company
focused on delivering innovative therapies to patients with kidney
disease through the biology of hypoxia inducible factor (HIF), today
announced that it has been selected for addition to the NASDAQ
Biotechnology Index® (Nasdaq:^NBI). The annual re-ranking of
the NASDAQ Biotechnology Index will become effective upon market open on
Monday, December 22, 2014.
The NASDAQ Biotechnology Index is designed to track the performance of a
set of securities listed on The NASDAQ Stock Market® (NASDAQ®)
that are classified as either biotechnology or pharmaceutical according
to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology
Index is calculated under a modified capitalization-weighted methodology
and ranked on an annual basis. All securities in the NASDAQ
Biotechnology Index are listed on the NASDAQ Global Market or the NASDAQ
Global Select Market, and meet minimum market value and share volume
requirements among other criteria.
The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ
Biotechnology Index(SM) Fund. In addition, options based on the iShares
NASDAQ Biotechnology Index Fund trade on various exchanges. For more
information about the NASDAQ Biotechnology Index visit www.nasdaq.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered
in Cambridge, Massachusetts, focused on delivering innovative therapies
to patients with kidney disease through HIF biology. Akebia's lead
product candidate, AKB-6548, is a once-daily, oral therapy, which has
completed a Phase 2b study for the treatment of anemia related to CKD in
non-dialysis patients and is in a Phase 2 study for the treatment of
anemia in patients undergoing dialysis. For more information on Akebia,
please visit www.akebia.com.
Investors:
Akebia Therapeutics, Inc.
Nicole P. Jones, +1-617-871-1210
Senior
Director, Investor Relations and Corporate Communications
njones@akebia.com
Media:
Argot Partners
Eliza Schleifstein, +1-917-763-8106
Eliza@argotpartners.com
Source: Akebia Therapeutics, Inc.
News Provided by Acquire Media
